Vaxcyte (NASDAQ:PCVX) Shares Down 3.7% – Should You Sell?

by · The Markets Daily

Shares of Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) fell 3.7% during mid-day trading on Thursday . The stock traded as low as $45.88 and last traded at $45.9440. 161,117 shares traded hands during trading, a decline of 91% from the average session volume of 1,747,154 shares. The stock had previously closed at $47.70.

Analyst Ratings Changes

PCVX has been the subject of a number of research analyst reports. Cowen restated a “buy” rating on shares of Vaxcyte in a report on Thursday, August 7th. The Goldman Sachs Group started coverage on Vaxcyte in a report on Friday, September 12th. They issued a “neutral” rating and a $38.00 price objective on the stock. Leerink Partners set a $77.00 target price on Vaxcyte and gave the stock an “outperform” rating in a report on Wednesday, November 19th. BTIG Research reissued a “buy” rating and issued a $85.00 target price on shares of Vaxcyte in a research report on Monday, November 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Tuesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $97.83.

Read Our Latest Analysis on PCVX

Vaxcyte Stock Performance

The company has a market capitalization of $5.97 billion, a price-to-earnings ratio of -9.40 and a beta of 1.28. The firm has a fifty day moving average price of $43.66 and a 200-day moving average price of $36.93.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.29). During the same period last year, the company earned ($0.83) EPS. On average, sell-side analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. AlphaQuest LLC acquired a new stake in shares of Vaxcyte in the 1st quarter valued at $33,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Vaxcyte during the 1st quarter worth $35,000. Allworth Financial LP lifted its position in shares of Vaxcyte by 148.9% during the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock worth $44,000 after buying an additional 731 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in Vaxcyte in the third quarter valued at about $45,000. Finally, CIBC Private Wealth Group LLC grew its position in Vaxcyte by 22,500.0% in the third quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after acquiring an additional 1,350 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Company Profile

(Get Free Report)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Featured Articles